Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision: v3.4.3 has been added. No visible changes to the study details or page layout were observed.
    Difference
    0.0%
    Check dated 2026-03-12T20:14:02.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    36 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the page. The previous items, including a government-funding operating-status notice and Revision: v3.4.1, were removed.
    Difference
    0.4%
    Check dated 2026-02-11T23:58:06.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Added a government funding notice and updated the site revision to v3.4.1; these are general page-wide updates and do not alter study details or eligibility criteria.
    Difference
    0.4%
    Check dated 2026-02-04T11:21:25.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now includes a Show glossary option and updated metadata: Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T07:29:49.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Administrative revision notes updated from v3.3.3 to v3.3.4, with no changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T03:05:06.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    Added a Locations section listing California, Illinois, Maryland, Massachusetts, Ohio, Tennessee, Texas, and Utah, and updated the page version to v3.3.3. Removed the prior location sections for those states and the HHS Vulnerability Disclosure, corresponding to the v3.3.2 changes.
    Difference
    0.9%
    Check dated 2025-12-23T22:00:43.000Z thumbnail image

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.